Metixene (brand names Methixart, CholinFall, Tremonil, Trest), also known as methixene, is an anticholinergic used as an antiparkinsonian agent.[2] It has also been reported to induce incomplete autophagy and cell death in metastatic cancer and brain metastases. [3]

See also

References

  1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. ^ Morton IK, Hall JM (1999). "Metixene". Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Dordrecht: Springer Netherlands. p. 178. ISBN 978-94-011-4439-1.
  3. ^ Fares, Jawad (2023). "Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases". Journal of Clinical Investigation. doi:10.1172/JCI161142. PMC 10721147. PMID 37847564. Retrieved 3 November 2023.